In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference, join our newsletter list.
We’ve reached the Wednesday of JPM Week, when gaits get sluggish, voices go hoarse, and early-morning meetings run an increasing risk of cancelation. Persevere. And while you’re at it, don’t miss STAT’s multimedia coverage of the conference, featuring decidedly lively interviews, commentary, and on-the-ground reportage.
The consensus is that the dark skies over biopharma are clearing
Maybe it’s the abundance of sunlight that filled San Francisco this week. More likely, it’s the surge of deals that came in December. But the sentiment around Union Square has been markedly more positive this year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect